2025 Annual Performance Preliminary Loss Announcement
Securities code: 688553 Securities abbreviation: Huiyu Pharmaceutical Announcement number: 2026-007
Sichuan Huiyu Pharmaceutical Co., Ltd.
Annual performance pre-loss announcement
2025
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.
1. Performance forecast for this period
(1) Performance forecast period
January 1, 2025 to December 31, 2025.
(2) Performance forecast
(1) According to preliminary calculations by the financial department, it is expected to achieve operating income of 960 million yuan to 1.09 billion yuan in 2025, a year-on-year decrease of 12.28% to a decrease of 0.40% compared with the same period last year (statutory disclosure data).
(2) The net profit attributable to the owners of the parent company is expected to be a loss of RMB 29 million to a loss of RMB 24 million in 2025, a year-on-year decrease of 108.91% to a decrease of 107.38% compared with the same period last year (statutory disclosure data).
(3) The net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be RMB 78 million to RMB 93 million in 2025, a year-on-year decrease of 15.33% to an increase of 0.96% compared with the same period last year (statutory disclosure data).
(3) The financial data related to this performance forecast have not been audited by a certified public accountant.
2. Performance of the same period last year
Total profit: 349.6989 million yuan. The net profit attributable to the owners of the parent company was RMB 325,390,300; the net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, was RMB 92,117,100.
Earnings per share: 0.77 yuan/share.
3. Main reasons for changes in performance in this period
The company's invested enterprise, Zhejiang Yuantuankang Pharmaceutical Co., Ltd., was listed on the Hong Kong Stock Exchange on August 20, 2024 (stock code: 02410.HK) in accordance with the 18A listing standards of the Hong Kong Exchange. The fluctuation in the stock price of the invested enterprise affected the fair value change loss of 173 million yuan during the reporting period.
4. Risk warning
The financial data related to the company's performance forecast have not been audited by a certified public accountant and are preliminary accounting data based on the financial department's own professional judgment. As of the disclosure date of this announcement, the company has not discovered any major uncertain factors that affect the accuracy of this performance forecast.
5. Other explanations
The above forecast data are only preliminary accounting data. The specific and accurate financial data shall be based on the company's officially disclosed audited annual report for 2025. The stock price fluctuations of the company's invested enterprise Zhejiang Yuankang Pharmaceutical Co., Ltd. will directly affect the company's income from changes in fair value and may have a significant impact on the company's financial statements. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Sichuan Huiyu Pharmaceutical Co., Ltd.
January 30, 2026